Uncategorized
$6.7m awarded to pancreatic cancer research projects

The Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) is awarding $6.7 million to eight projects in 2026.
The funded projects span the full continuum of pancreatic cancer research, from prevention and early detection to next-generation therapies.
“Every investment we make is driven by one goal: to urgently end pancreatic cancer,” said A Emmet Stephenson Jr, Co-Founder of SGPCRI. “Our mission is to identify, fund, and accelerate the most innovative research in the field, wherever it exists. By empowering exceptional scientists to pursue transformative ideas, we hope to speed the discoveries that will prevent pancreatic cancer, detect it earlier, and deliver more effective treatments to patients worldwide.”
The Stephenson Global Pancreatic Cancer Research Institute was established in honour of Toni Lyn Stephenson, who passed away from pancreatic cancer in 2020. Inspired by her legacy, the family made a $150 million commitment, representing approximately two-thirds of the funding currently directed toward pancreatic cancer research, to accelerate the most innovative science.
“We created SGPCRI to support investigators who are willing to challenge conventional thinking and pursue ideas with the potential to fundamentally change pancreatic cancer outcomes,” said Tessa Stephenson Brand, Co-Founder of SGPCRI.
Award recipients
The 2026 Stephenson Global Scholar Grant recipients will include:
- Jenn Abelin, Senior Group Leader of the Proteomics Platform at the Broad Institute of MIT and Harvard, and William Freed-Pastor, Assistant Professor of Medicine at Harvard Medical School and physician-scientist at Dana-Farber Cancer Institute: Their work will identify hidden tumour antigens displayed by pancreatic cancer cells to advance next-generation cancer vaccines and T-cell therapies.
- Erik Knudsen, Professor of Oncology, Senior Vice President, Associate Director Oo Basic Science Research, and Chair of the Department of Molecular and Cellular Biology at Roswell Park Comprehensive Cancer Center, and Agnieszka Witkiewicz, Professor of Oncology and Director of the Advanced Tissue Imaging Shared Resource at Roswell Park Comprehensive Cancer Center: Their work will target key regulators of cell division to prevent and overcome resistance to RAS-targeted therapies for pancreatic cancer.
- Shohei Koide, Professor of Biochemistry and Molecular Pharmacology and Director of Cancer Biologics at NYU Grossman School of Medicine and NYU Perlmutter Cancer Center: His work will advance antibodies targeting the protein LCN2 to help immune cells infiltrate and attack pancreatic tumours.
- Leyuan Ma, Assistant Professor in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania and Children’s Hospital of Philadelphia: His work will engineer vaccine-boosted T cells to overcome pancreatic tumours’ immunosuppressive defences and activate the body’s own anti-tumour immune response, with the goal of developing an off-the-shelf immunotherapy.
- Cristian Prieto-García, Ramón y Cajal group leader at the Institute of Biomedicine of Seville (IBiS) and the University of Seville, Spain: His work will evaluate next-generation splicing inhibitors designed to exploit a unique vulnerability in pancreatic cancer cells, causing them to accumulate toxic proteins and die while sparing healthy cells.
The post $6.7m awarded to pancreatic cancer research projects appeared first on Drug Discovery World (DDW).
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized6 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read